3. Sanofi and Covance

3. Sanofi and Covance:

In 2010, when it was Sanofi-Aventis, the pharma giant ($SNY) was in need of revamping its R&D structure and looked toward outsourcing to take a load off its back. At some point, Sanofi must have noticed the sweet $1.6 billion deal Covance ($CVD) made with Eli Lilly ($LLY) in 2008 and figured that forging a similar partnership with the CRO was the way to go. The agreement between Covance and Lilly was the only CRO/Pharma partnership to make FierceBiotech's top 10 deals of 2008 list, after all.

Thanks to the $2.2 billion deal, Sanofi-Aventis and Covance formulated a 10-year partnership that gave each entity something more to sink its teeth into. For Covance, the deal allowed it to purchase two of Sanofi's European facilities for $25 million and acquire the pharma's (CMC) chemistry, manufacturing and controls services. In return, Sanofi gained access to Covance's global R&D portfolio of discovery support, toxicology, chemistry, clinical Phase I-IV, central laboratory and market access services.

3. Sanofi and Covance

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.